TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06003868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy
Description: Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy-assisted physiotherapy
Description: The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level.
Study: NCT05495100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone liposome、Chidamide、Azacitidine
Description: Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1\~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
Study: NCT05565833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi OASIS
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient Education
Description: An educational website containing information on insomnia
Study: NCT06363344

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999)
Description: An advanced practice nurse who is a member of the PICU team monitors patients by questionnaires at 1 and 3 months. Depending on the anomalies detected, whether at the somatic, psychological, emotional or social level, the nurse refers to competent specialists and collaborators and continues monitoring of the family as needed.
Study: NCT05107908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Implicit Priming
Description: Approximately 10-minute behavioral intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Implicit Priming
Description: Approximately 10-minute behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Exposure Task
Description: Approximately 10-30 minute behavioral intervention
Study: NCT06024174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986466
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986466
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986466
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days
Study: NCT05756660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.
Study: NCT04812041

Intervention type: OTHER
Intervention: CAM-ICU 7 score
Description: A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.

Intervention type: OTHER
Intervention: 4C Mortality Score
Description: 4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
Study: NCT05348772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmnioPul-02
Description: Mesenchymal stem / stromal cells, MSC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmnioPul-02
Description: Mesenchymal stem / stromal cells, MSC
Study: NCT05655689

Intervention type: DRUG
Intervention: Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution
Description: In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Ceftazidime 5% + vancomycin 5%
Description: In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Gentamicin 1.4% + vancomycin 5%
Description: In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Natamycin 5% Oph Susp
Description: In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Voriconazole 1%
Description: In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Natamycin 5% + voriconazole 1%
Description: In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Natamycin 5%+ ceftazidime 5% + vancomycin 5%
Description: In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.

Intervention type: DRUG
Intervention: Voriconazole 1% + ceftazidime 5% + vancomycin 5%
Description: In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05245526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS
Description: Reprocessed noninvasive pulse oximeter sensors.
Study: NCT05775393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block for MRM
Description: They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block for MRM
Description: They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study.
Study: NCT06192862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of screening intention and Transtheoretical Model stages for CRC screening
Description: Screening Intentions will be measured by asking the subject, How much do you agree or disagree: I am intending to have colon cancer screening within the next 6 months. Subjects who strongly disagrees or somewhat disagrees are considered not having screening intention. Subjects who somewhat agrees or strongly agrees are considered having screening intention. For subjects who has screening intention, they will be asked if they have plan to arrange a consultation with primary care physician to collect FIT kits in next 3 months.
Study: NCT06237530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visceral body scan (VBS)
Description: The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord \& Garfinkel, 2022)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Somatosensory body scan (SBS)
Description: The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: External control meditation (ECM)
Description: The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment.
Study: NCT06237569

Intervention type: DRUG
Intervention: Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia
Description: A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth.

Intervention type: DRUG
Intervention: Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia
Description: A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth.

Intervention type: DRUG
Intervention: Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia
Description: A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth.
Study: NCT05392205

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.
Study: NCT06308458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breather Exerciser Trainer
Description: Gradual intensity from 2-3 rate of perceived exertion (RPE) up to reach 5-7 RPE, with gradual frequency; 1st week 8 sets of 5 repetitions '1 minute rest', 2nd week be 9 sets, and 3rd week reach 10 sets of 5 repetitions. then from 4-8 weeks 'end of study protocol' will be 10 sets of 6 repetitions with 1 minute rest between sets.), along with conventional breathing exercises (Diaphragmatic breathing, Pursed-up breathing, and Exercise connected with respiration), for 5 sessions per week for eight weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Breathing Exercise
Description: Diaphragmatic breathing; place one hand on upper chest and the other on belly. Patient Breathe in slowly through nose, letting the air in deeply towards lower belly then patient is asked to tighten abdominal muscles and let them fall inward during exhalation through pursed lips Pursed-up breathing; by inhales through nose and exhales over 4 and 6 seconds in a whistling position Exercise connected with respiration; repetitive bilateral shoulder flexion then repetitive bilateral shoulder abduction, synchronized with breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Breathing Exercise
Description: Diaphragmatic breathing; place one hand on upper chest and the other on belly. Patient Breathe in slowly through nose, letting the air in deeply towards lower belly then patient is asked to tighten abdominal muscles and let them fall inward during exhalation through pursed lips Pursed-up breathing; by inhales through nose and exhales over 4 and 6 seconds in a whistling position Exercise connected with respiration; repetitive bilateral shoulder flexion then repetitive bilateral shoulder abduction, synchronized with breathing
Study: NCT05812209

Intervention type: PROCEDURE
Intervention: Stellate Ganglion Block
Description: Ultrasound guided block of the Stellate Ganglion with local anesthetics.
Study: NCT05005572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Payment adjustment for home dialysis and transplant
Description: The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
Study: NCT04735627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levodopameter
Description: There are several minimally-invasive sensors being developed that can detect levodopa levels in the capillary blood, sweat, and interstitial fluid.
Study: NCT05557253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced Anesthesia
Description: Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
Study: NCT06376344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release with tennis ball
Description: Movement of the Tennis Ball on the Sole of the Foot: The tennis ball is moved under the foot by back and forth movements and by applying pressure. The aim is to briefly keep the pressure of the ball on the body and the stress indicated by the massage on.
Study: NCT06052202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC mHealth
Description: Participants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
Study: NCT05315817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multiPlus dialysate
Description: Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
Study: NCT05124691

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albendazole and Ivermectin fixed dose coformulation
Description: 400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole 400mg single dose
Study: NCT06052202

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
Study: NCT05841563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM54
Description: PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion
Study: NCT05126875

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Repeated stereotactic radiosurgery
Description: Repeated stereotactic radiosurgery to recurring brain metastases
Study: NCT05058742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuriStim
Description: Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
Study: NCT05627505

Intervention type: DIAGNOSTIC_TEST
Intervention: metagenomic next-generation sequencing
Description: Collection of bronchoalveolar lavage fluid

Intervention type: DIAGNOSTIC_TEST
Intervention: metagenomic next-generation sequencing
Description: Collection of bronchoalveolar lavage fluid
Study: NCT04867122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention-matched Control
Description: Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team.

Intervention type: OTHER
Group type: OTHER
Intervention: In-depth interviews
Description: The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.